In January 2022 Aescap will launch its second fund called Aescap Genetics. The Genetics fund will invest exclusively in the fast-growing market of RNA, gene and cell therapy medicines. The advantage of Genetics medicines is their ability to treat diseases at their root cause. They are not only able to treat diseases better but can also treat diseases for which no medicines are available today.
Around 125 public companies have so far launched 50 Genetics medicine and almost 900 others are being tested in humans, and these numbers are growing rapidly.
Aescap has invested in public Genetics companies since 2016 and has generated a preferred return. Aescap Genetics invests in approximately 15 companies that each have the capacity to minimally double in value over 3-4 years.